natgillin/translations-raw huggingface dataset:
Slowly and gently push the plunger down to gently squirt the medicine into the inside of your cheek and swallow it.
Počasi in nežno potisnite bat navzdol ter nežno iztisnite zdravilo v usta proti notranji strani lic in ga pogoltnite.
Slowly and gently push the plunger rod up to get the air out of the pre-filled syringe.
Počasi in previdno potisnite bat brizge navzgor, da boste iztisnili zrak iz napolnjene injekcijske brizge.
Slowly and gently rock the pen side to side 5 times to mix the medicine (like a windscreen wiper).
Počasi in previdno 5-krat zanihajte peresnik z ene strani na drugo (premikanje, podobno avtomobilskemu brisalcu), da boste zmešali zdravilo.
Slowly depress the plunger rod to inject all the solvent into the ALPROLIX vial.
Nosilec za bat brizge počasi potiskajte, da injicirate celotno količino vehikla v vialo z zdravilom ALPROLIX.
SLOWLY depress the plunger to eliminate all the bubbles and to expel the excess drug so that the top edge of the 3rd rib on the plunger stopper aligns with the pre-printed black dosing line (See Fig 2, below).
POČASI potisnite bat, da odstranite vse zračne mehurčke in odvečni volumen zdravila, tako da je zgornji rob tretjega rebra na gumijastem tesnilu poravnan z natisnjeno črno odmerno črto (glejte sliko 2 spodaj).
Slowly dispense the content of the syringe into an infusion bag containing 50 mL of sodium chloride 9 mg/mL (0.9%) solution for infusion.
Vsebino brizge počasi dajte v infuzijsko vrečico, ki vsebuje 50 ml raztopine natrijevega klorida 9 mg/ml (0,9 %) za infundiranje.
Slowly inject all the water from the syringe into the vial.
Počasi injicirajte vso vodo iz injekcijske brizge v vialo.
Slowly inject into the gluteal or deltoid muscle.
Počasi injicirajte v glutealno ali deltoidno mišico.
Slowly inject the 6.0 ml sodium chloride 0.9%, solution for injection, into the reconstituted NovoThirteen vial.
Počasi injicirajte 6,0 ml 0,9 % raztopine natrijevega klorida za injiciranje v vialo s pripravljenim zdravilom NovoThirteen.
Slowly inject the recommended volume as a single intramuscular injection into the gluteal or deltoid muscle.
Počasi injicirajte priporočeno količino kot enkratno intramuskularno injekcijo v glutealno ali deltoidno mišico.
Slowly inject the reconstituted Myozyme directly into the sodium chloride 9 mg/ml (0.9%) solution for injection.
Počasi vbrizgavajte rekonstituirano zdravilo Myozyme neposredno v natrijev klorid 9 mg/ml (0,9 %), raztopino za injiciranje.
Slowly inject the solvent into the vial containing the powder.
Vehikel počasi injicirajte v vialo s praškom.
Slowly pull back the plunger rod to withdraw as much medicine as possible from the vial.
Bat brizge počasi izvlecite iz brizge, da boste iz viale lahko izvlekli kar največ zdravila.
Slowly pull back the plunger to withdraw a bit more than the dose prescribed by your doctor into the syringe.
Bat počasi potegnite nazaj in v brizgo zajemite malo več kot odmerek, ki vam ga je predpisal zdravnik.
Slowly pull back the plunger until the solution reaches the 1.0 ml mark.
Počasi izvlecite bat, dokler raztopina ne doseže oznake 1,0 ml.
Slowly pull the plunger back down to the dose prescribed by your doctor.
Nato spet počasi povlecite bat navzdol, da se poravna z oznako za vaš odmerek.
Slowly pull the plunger back to draw the liquid into the syringe (see Diagram 9).
Počasi potegnite bat nazaj, da izvlečete raztopino v brizgo (glejte sliko 9).
Slowly pull the plunger back to the 10 mL mark on the syringe (see Figure 2).
Počasi potegnite bat nazaj do oznake 10 ml na brizgi (glejte sliko 2).
Slowly pull the plunger until all the liquid is in the syringe.
Počasi vlecite bat, dokler ni vsa tekočina v injekcijski brizgi.
Slowly pull the syringe plunger up to the correct mark (0.2 ml to 1.0 ml), filling the syringe with Ilaris solution.
Počasi potegnite bat brizge navzgor do pravilne oznake (od 0,2 ml do 1,0 ml) in tako napolnite brizgo z raztopino Ilaris.
Slowly push back on the plunger to leave only the amount prescribed by your healthcare professional.
Počasi potisnite nazaj na bat, da v brizgi pustite le količino, ki vam jo je predpisal zdravnik.
Slowly push back the plunger all the way in.
Počasi potisnite bat v brizgo do konca.
Slowly push in the plunger of the syringe to inject the water into the vial.
Počasi potiskajte bat brizge, da vodo injicirate v vialo.
Slowly push the grey needle completely into your skin at an angle of about 45 to 90 degrees – then let go of your skin.
Sivo iglo počasi v celoti potisnite v kožo pod kotom okoli 45 do 90 stopinj - nato kožo spustite.
Slowly push the needle into the skin entirely (1).
Počasi zabodite celo iglo v kožo (1).
Slowly push the plunger all the way down so the medicine goes into the child’s mouth.
Počasi potiskajte bat do konca, tako da bo šla celotna količina zdravila v otrokova usta.
Slowly push the plunger all the way down to give all the medicine in the oral dispenser.
Počasi potisnite bat do konca da date vso zdravilo iz odmernika.
Slowly push the plunger all the way down until the syringe is empty. (See Figure J.)
Počasi potiskajte bat do konca navzdol, dokler ni injekcijska brizga prazna. (Glejte sliko J.)
Slowly push the plunger all the way down.
Počasi potiskajte bat navzdol do konca.
Slowly push the plunger all the way in.
Počasi potiskajte bat navzdol do konca.
Slowly push the plunger all the way into the syringe.
Počasi potiskajte bat do vrha brizge.
Slowly push the plunger in one smooth motion until syringe is empty.
Počasi in z enim samim enakomernim gibom potiskajte bat, dokler ni injekcijska brizga prazna.
Slowly push the plunger of the smaller syringe with the recombinant human hyaluronidase at an initial rate per infusion site to approximately 1 to 2 ml per minute and increase as tolerated.
Počasi potisnite bat manjše injekcijske brizge z rekombinantno humano hialuronidazo z začetno hitrostjo na mesto infundiranja približno 1 do 2 ml na minuto, ki jo povečujte, kolikor jo lahko prenašate.
Slowly push the plunger of the syringe with a steady hand until all the fluid is injected into the skin and no liquid remains in the syringe.
Z mirno roko počasi potiskajte bat brizge, dokler se pod kožo ne injicira celotna tekočina in v brizgi ni več tekočine.
Slowly push the plunger to empty the liquid from the syringe into the mixing cup (see Figure 5).
Počasi potiskajte bat, da boste tekočino iz brizge iztisnili v posodico za mešanje (glejte sliko 5).
Slowly push the plunger to give all of the dose (see Figure 11).
Počasi potiskajte bat, da boste dali celotni odmerek (glejte sliko 11).
Slowly push the plunger until you see a small amount of liquid at the tip of the syringe.
Počasi potiskajte bat, dokler na konici brizge ne zagledate majhne količine tekočine.
Slowly push the plunger up to force the air bubble out of the syringe without inadvertently expelling solution.
Počasi potiskajte bat navzgor, da iz injekcijske brizge iztisnete zračne mehurčke, ne da bi pri tem nehote iztisnili raztopino.
Slowly push the plunger with the thumb while holding the syringe with the forefinger and the middle finger against the finger grips until all the medicine is injected.
Bat po asi s palcem potiskajte navznoter, medtem ko injekcijsko brizgo držite s konicami kazalca in sredinca, dokler ne injicirate celotnega odmerka zdravila.
Slowly pushing the plunger all the way into the oral syringe.
Počasi potiskajte bat v brizgo do konca.
Slowly relax the pressure of your thumb on the plunger head and allow it to move your thumb back upwards.
Pritisk palca na glavo bata počasi popustite in mu omogočite, da potisne palec nazaj navzgor.
Slowly release the plunger and allow the needle guard to automatically cover the exposed needle.
Počasi sprostite bat in pustite, da zapiralo igle samodejno pokrije odkrito iglo.
Slowly swirl the vial to allow reconstitution of the lyophilised powder.
Vialo počasi vrtite, da se liofiliziran prašek lahko raztopi.
Slowly take your thumb off the plunger head to allow the empty pre-filled syringe to move up until the entire needle is covered by the needle guard, as shown by the figure 9:
Počasi snemite palec z glave bata, da se bo prazna napolnjena injekcijska brizga pomaknila navzgor, dokler ne bo vsa igla prekrita s ščitnikom igle, kakor je prikazano na sliki 9:
Slowly take your thumb off the plunger head to allow the empty syringe to move up until the entire needle is covered by the needle guard, as shown by Figure 7:
Počasi umaknite palec z glave bata, da se prazna brizga pomakne navzgor, dokler ni cela igla prekrita s ščitnikom, kot je prikazano na Sliki 7:
Slowly withdraw the appropriate amount of reconstituted drotrecogin alfa (activated) solution from the vial.
Počasi potegnite ustrezno količino pripravljene raztopine drotrekogina alfa (aktiviranega) iz viale.
Slowly withdraw the desired amount.
Počasi izvlecite željeno količino.
Slowly withdraw the plunger in the syringe to withdraw the medicine from the vial.
Počasi izvlecite bat brizge in izvlecite zdravilo iz viale.
Slowly withdraw the recommended volume from the vial into the luer lock syringe to allow for injection.
Priporočeno količino izvlecite iz viale v injekcijsko brizgo z nastavkom Luer Lock, da omogočite injiciranje.
Sluggishness
upočasnjenost
sluggishness (0.2% vs 0%)
upočasnjenost (0,2% v primerjavi z 0%)
Small amounts (0.5-2%) of additional metabolites were found in the urine.
V seču so našli tudi majhne količine (0,5–2 %) drugih presnovkov.
Small amounts of air may be present in the needle and insulin reservoir during normal use.
Med normalno uporabo je lahko v igli in insulinskem rezervoarju nekaj malega zraka.
Small amounts of air may collect in the needle and cartridge during normal use.
Med normalno uporabo se lahko v igli in injekcijskem vložku nabere nekaj malega zraka.
Small amounts of air may collect in the needle and cartridge during normal use.
Pri normalni uporabi se v injekcijski igli in vložku lahko nabere manjša količina zraka.
Small amounts of blood will be drawn before treatment, 6 months and 12 months after treatment to measure how your body’s immune (defence) system is responding to the treatment with Glybera.
Pred zdravljenjem ter 6 mesecev in 12 mesecev po zdravljenju vam bodo odvzeli majhno količino krvi, s čimer bodo izmerili, kako se vaš imunski sistem odziva na zdravljenje z zdravilom Glybera.
Small bleedings in your skin due to blood clots
majhne krvavitve v koži, ki so posledica krvnih strdkov
Small bleedings in your skin due to blood clots
majhne krvavitve v koži, ki so posledica krvnih strdkov,
Small bowel obstruction
Zapora tankega črevesa
Small bowel, hepatic, colorectal and pancreatic tumours
tumorjev tankega črevesa, jeter, debelega črevesa in pankreasa
Small breaks in the surface of the eye, with or without inflammation
majhne razpoke na površini očesa z vnetjem ali brez njega,
Small bubbles are okay and do not need to rise to the top.
Majhni mehurčki so v redu in ni treba, da pridejo na vrh.
Small bubbles or foam around the edge of the vial are common.
Majhni mehurčki ali pena okrog roba viale so nekaj običajnega.
Small Cell Lung Carcinoma Initial dose
Drobnocelični pljučni karcinom Začetni odmerek
SMALL CHILDREN SHOULD NOT TOUCH THE DOG FOR 72 HOURS (3 days)
MAJHNI OTROCI SE NE SMEJO DOTIKATI PSA 72 UR (3 dni) PO DAJANJU
Small dog
Majhni psi
small dogs
majhni psi
Small dogs (5 to 10 kg)
Majhni psi (5 do 10 kg)
Small Fiber change from BL
Sprememba pri tankih vlaknih glede na izhodišče
Small improvements in BMD were noted at 48 weeks after switching to E/C/F/TAF compared to maintaining the tenofovir disoproxil fumarate-containing regimen.
V primerjavi z režimom, ki vsebuje dizoproksiltenofovirat fumarat, so po prehodu na E/C/F/TAF po 48 tednih zdravljenja opazili majhno izboljšanje MGK.
Small increases in serum PTH levels were observed with increases being larger in subjects with higher baseline PTH concentrations.
Opažali so majhna zvišanja koncentracije PTH v serumu; zvišanja so bila večja pri preiskovancih z večjo izhodiščno koncentracijo PTH.
Small increases in serum PTH levels were observed with increases being larger in subjects with higher baseline PTH concentrations.
Poročali so o majhnih povečanjih vrednosti PTH v serumu, ki so bila izrazitejša pri preiskovancih z večjo izhodiščno koncentracijo PTH.
Small intestinal bacterial
bakterijsko preraščanje v tankem
Small intestinal obstruction
obstrukcija tankega črevesa
small intestinal perforation
perforacija tankega črevesa
Small Intestine
Tanko črevo
Small Intestine
želodčna stena
Small intestine wall
Stena tankega črevesa
Small Intestine1
tanko črevo1
Small mean increases in heart rate of 2 to 4 beats per minute (bpm) and a 1.3% and 1.4 % incidence of sinus tachycardia, with a concomitant increase from baseline ≥ 15 bpm, were observed with dulaglutide 0.75mg and 1.5 mg, respectively.
Pri zdravljenju z dulaglutidom 0,75mg in 1,5 mg so opazili majhna povprečna povečanja hitrosti srčnega utripa za 2 do 4 utripe na minuto (bpm) ter 1,3% oziroma 1,4 % incidenco sinusne tahikardije, s sočasnim povečanjem od izhodišča ≥ 15 bpm.
Small mean reductions in haemoglobin [– 0.95 g/dL (95% CI: –1.38, –0.53)] and platelet count [-44.1 × 109/L (95% CI: –57.6, –30.7)] were observed between baseline and end of study.
Med izhodiščem in koncem študije so opazili majhno povprečno zmanjšanje hemoglobina [–0,95 g/dl (95-odstotni IZ: –1,38, –0,53)] in število trombocitov [–44,1 × 109/l (95-odstotni IZ: –57,6, –30,7)].
Small Needle Protector
Manjša zaščita igle
Small observed increases in AUC(0-24hr), by about 30% to 40% in mild to moderate renal impairment, compared to a patient with normal renal function, and lack of accumulation of drug with multiple doses irrespective of renal function, suggest that dose adjustments of zoledronic acid in mild (Clcr = 50–80 ml/min) and moderate renal impairment down to a creatinine clearance of 35 ml/min are not necessary.
Majhno zvečanje AUC(0-24hr) za okrog 30 do 40 %, ki so ga opazili pri bolnikih z blago do zmerno ledvično okvaro v primerjavi z bolniki z normalnim ledvičnim delovanjem, in odsotnost kopičenja zdravila ob večkratnih odmerkih, ne glede na ledvično delovanje, kažeta, da prilagajanje odmerka zoledronske kisline pri blagi (Clcr = 50 do 80 ml/min) in zmerni ledvični okvari z znižanim očistkom kreatinina do 35 ml/min ni potrebno.
Small particles may be visible in the solution and will not affect the effectiveness of the medicinal product.
V raztopini lahko ostanejo vidni majhni delci, ki ne bodo vplivali na učinkovitost zdravila.
Small purple spots on the skin (purpura)
drobne vijoličaste pike po koţi (purpura)
Small red bruises on the skin (ecchymoses)
Majhne rdeče modrice na koži (ekhimoza)
Small subcutaneous injection site nodules were observed very frequently in clinical trials, consistent with the known properties of poly (D,L-lactide co-glycolide) polymer microsphere formulations.
V kliničnih študijah so se na mestu injiciranja zelo pogosto pojavili majhni podkožni noduli, kar je skladno z znanimi lastnostmi poli (D,L-laktid koglikolid) polimernih mikrosfernih formulacij.
Small superficial basal cell carcinomas (sBCCs) in adults.
majhnih površinskih karcinomov bazalnih celic (sBCCs) pri odraslih bolnikih
Small white particles may be present.
Lahko so prisotni majhni beli delci.
Smallpox was officially declared eradicated in 1980 with the last known case of the disease occurring in 1977.
Črne koze so bile uradno razglašene za izkoreninjeno bolezen leta 1980, zadnji znani primer bolezni pa je iz leta 1977.
SMART was a multi-centre, randomised, double blind, placebo-controlled, parallel group 28-week study in the US which randomised 13,176 patients to salmeterol (50 micrograms twice daily) and 13,179 patients to placebo in addition to the patients’ usual asthma therapy.
SMART je bila 28-tedenska multicentična, randomizirana, dvojno slepa, s placebom nadzorovana študija s paralelnimi skupinami v ZDA, v kateri je bilo 13.176 bolnikov randomiziranih za salmeterol (50 mikrogramov dvakrat na dan) in 13.179 bolnikov za placebo, poleg običajnega zdravljenja, ki so ga bolniki uporabljali za astmo.
Smithfield, Rhode Island 02917 U.S.A.
Smithfield, Rhode Island 02917 ZDA
SmithKline Beecham Ltd 980 Great West Road
SmithKline Beecham Ltd, 980 Great West Road
Smoke cessation
Bupropion
Smokers (smoking is a moderate CYP1A2 inducer)
Kadilci (kajenje je srednje močen induktor CYP1A2)
Smokers:
Kadilci
Smokers: Cigarette smoking has been shown to reduce erlotinib exposure by 50-60%.
Kadilci: pokazalo se je, da kajenje cigaret zmanjša izpostavljenost erlotinibu za 50 do 60 %.
Smoking cessation aids
Zdravila za pomoč pri opuščanju kajenja
Smoking cessation with or without treatment is associated with various symptoms.
Prenehanje kajenja lahko spremljajo različni simptomi, tako z zdravljenjem kot brez njega.
Smoking greatly increases the rate and extent of absorption of inhaled human insulin (Cmax about 3 to 5 times and AUC about 2 to 3 times higher) and therefore could increase the risk of hypoglycaemia (see sections 4.3 and 4.5).
Kajenje močno poveča delež in obseg absorpcije humanega insulina za inhaliranje (Cmax je za 3- do 5- krat večja, AUC za 2- do 3- krat večja) in bi zato lahko povečalo tveganje za hipoglikemijo (glejte poglavje 4.3).
Smoking greatly increases the rate and extent of absorption of inhaled human insulin (Cmax about 3 to 5 times and AUC about 2 to 3 times higher) and therefore could increase the risk of hypoglycaemia (see sections 4.3 and 4.5).
Kajenje močno poveča delež in obseg absorpcije humanega insulina za inhaliranje (Cmax je za 3- do 5- krat večja, AUC za 2- do 3- krat večja) in bi zato lahko povečalo tveganje za hipoglikemijo (glejte poglavji 4.3 in 4.5).
Smoking in relation to induced alteration in pharmacokinetics
kajenju v zvezi s povzročenimi spremembami farmakokinetike,
Smoking induces CYP1A2; the clearance of cinacalcet was observed to be 36-38% higher in smokers than non-smokers.
Kajenje inducira CYP1A2; očistek cinakalceta pri kadilcih je za 36-38% večji kot pri nekadilcih.
Smoking status <0.0001 6.5 times higher in never smokers than ever-smokers
Kajenje < 0,0001 6,5-krat večji pri tistih, ki niso nikoli kadili, kot pri tistih, ki so kdaj kadili
Smoking was not assessed for Xeplion.
Vpliva kajenja pri zdravilu Xeplion niso preučevali.
Smokingcessation aids
Pripomočki za prenehanje kajenja
Smooth, off-white ointment.
Gladko sivobelo mazilo.
SmPC and patient information leaflets
Povzetkom glavnih značilnosti zdravila (SmPC) in navodilom za uporabo.
SmPC).
odmerek
SMPR (per patient year)
topnja hitrosti obolevnosti okostja (na bolnikova leta)
SMR per Year
DSO na leto
SMV = simeprevir.
SMV = simeprevir
SN-38 glucuronide is 3%.
SN-38 3 %.
SN-38 is approximately 1000 times as potent as irinotecan as an inhibitor of topoisomerase I purified from human and rodent tumour cell lines.
SN-38 je približno 1.000-krat močnejši kot irinotekan kot zaviralec topoizomeraze I, očiščene iz tumorskih celičnih linij človeka in glodavcev.
Snap off the plastic tab on the top of the vial containing sterile water for injection (solvent).
Odlomite plastični pokrovček na vrhu viale, ki vsebuje sterilno vodo za injekcije (vehikel).
SNAP!
TLESK
Snapshot date: 15 February 2012
Datum zajema podatkov: 15. februar 2012
Snoring
Smrčanje
SNRIs (serotonin noradrenaline reuptake inhibitors) used to treat depression and/or anxiety including venlafaxine, duloxetine.
Zaviralci SNRI (zaviralci ponovnega privzema serotonina in noradrenalina) se uporabljajo za zdravljenje depresije in/ali anksioznosti ter vključujejo venlafaksin in duloksetin.
So be especially careful if you take painkillers or anti-inflammatories while you’re taking Bondenza.
Če jemljete zdravila proti bolečini ali protivnetna zdravila med zdravljenjem z zdravilom Bondenza, bodite še posebno previdni.
So be especially careful if you take painkillers or anti-inflammatories while you’re taking Bonviva.
Če jemljete zdravila proti bolečini ali protivnetna zdravila med zdravljenjem z zdravilom Bonviva, bodite še posebno previdni.
So be especially careful if you take painkillers or anti-inflammatories while you’re taking Ibandronic Acid Teva.
Zato morate biti še posebej previdni, če med jemanjem zdravila Ibandronska kislina Teva vzamete tudi zdravila za lajšanje bolečin ali protivnetna zdravila.
So for every 2 kg (4 lb) you lose from dieting alone, alli chewable tablets can help you lose 1 kg (2 lb) more.
Tako vam za vsaka 2 kg, ki bi ju izgubili samo z dieto, alli žvečljive tablete lahko pomagajo izgubiti 1 dodaten kilogram.
So if you are taking Rapamune, you may therefore catch more infections than usual, such as infections of the skin, mouth, stomach and intestines, lungs and urinary tract (see list below).
Če jemljete zdravilo Rapamune, boste zato najbrž dobili več okužb kot ponavadi, na primer okužbe kože, ust, želodca in črevesa, pljuč in sečil (glejte seznam v nadaljevanju).
So when receiving any other treatment please tell the doctor that you are using DuoTrav.
Če torej prejemate kakršnokoli drugo zdravljenje, morate povedati zdravniku, da uporabljate zdravilo DuoTrav.
So, it is important to take appropriate precautions to prevent others from becoming infected with HBV.
Za preprečevanje prenosa okužbe s HBV na druge je pomembno, da še naprej izvajate ustrezne varnostne ukrepe.
Soap, alcohol, or other solvents should not be used to remove the hydrogel because they may enhance the active substances’ ability to penetrate the skin.
Za odstranjevanje hidrogela se ne sme uporabljati mil, alkohola ali drugih topil, ker bi lahko povečali prehajanje zdravilne učinkovine skozi kožo.
SOC = standard of care
SOC = standardni postopki oskrbe
SOC PI (n = 83):
Standardno zdravljenje s PI-ji (n = 83):
Social limitations
Družbene omejitve
Social relationships subscale
Podlestvica družbena razmera
Social relationships subscale
Podlestvica družbena razmerja
Socks: for feet and ankles.
Nogavice: za stopala in gležnje.
Sodium (as chloride and as phosphate)
Natrij (v obliki natrijevega klorida in natrijevega fosfata)
Sodium (Hypo)
Natrij (hipo)
Sodium acetate (E262) Sodium chloride Polysorbate 80 (E433) Edetate disodium (E386)
Natrijev acetat (E262) Natrijev klorid Polisorbat 80 (E433) Dinatrijev edetat (E386)
Sodium acetate (tri-hydrate)
natrijev acetat (trihidrat)
Sodium acetate anhydrous
Natrijev acetat, brezvodni
Sodium acetate Glacial acetic acid Sodium chloride Water for injections
natrijev acetat koncentrirana ocetna kislina natrijev klorid voda za injekcije
Sodium acetate trihydrate Acetic acid glacial Sucrose
natrijev acetat trihidrat ledocet
Sodium acetate trihydrate Glacial acetic acid Sodium chloride
Natrijev trihidrat acetat Koncentrirana ocetna kislina Natrijev klorid
Sodium acetate trihydrate Methionine
Natrijev acetat trihidrat Metionin
Sodium acetate trihydrate sodium chloride, glacial acetic acid and water for injections.
Natrijev klorid, koncentrirana ocetna kislina, natrijev acetat trihidrat in voda za injekcije.
Sodium acetate trihydrate Water for injections
koncentrirana ocetna kislina (ledocet) natrijev acetat trihidrat voda za injekcije
Sodium acetate trihydrate, acetic acid glacial, L-arginine hydrochloride, polysorbate 20, water for injections.
natrijev acetat trihidrat, koncentrirana ocetna kislina, L-argininijev klorid, polisorbat 20, voda za injekcije
Sodium and water retention and oedema tendency, hypertension, hypokalemia.
Zadrževanje natrija in vode ter nagnjenost k edemu, hipertenzija, hipokalemija.
Sodium and/or volume depleted patients
Bolniki s primanjkljajem natrija in/ali volumna telesnih tekočin
Sodium approximately 128.2 mmol/l (2.95 mg/ml).
Natrij približno 128,2 mmol/l (2,95 mg/ml).
Sodium benzoate (E211) Purified water
Natrijev benzoat (E211) Prečiščena voda
Sodium benzoate 1.5 mg
Natrijev benzoat 15 mg
Sodium benzoate 1.5 mg (equivalent to 0.05 mg per drop) For a full list of excipients, see section 6.1.
Natrijev benzoat 1,5 mg (kar ustreza 0,05 mg v 1 kapljici) Za celoten seznam pomožnih snovi glejte poglavje 6.1.
Sodium benzoate 1.5 mg (equivalent to 0.06 mg per drop) For a full list of excipients, see section 6.1.
Natrijev benzoat 1,5 mg (kar ustreza 0,06 mg v 1 kapljici) Za celoten seznam pomožnih snovi glejte poglavje 6.1.
Sodium benzoate 1.75 mg.
Natrijev benzoat 1,75 mg.
Sodium benzoate 1.75 mg/ml
Natrijev benzoat 1,75 mg/ml
Sodium benzoate 5 mg.
Natrijev benzoat 5 mg